KZIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kazia Therapeutics Ltd (KZIA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown strong regular market performance with a 16.45% increase, positive analyst sentiment with a raised price target, and encouraging clinical trial results. Despite the lack of recent news, the technical indicators and options data suggest bullish sentiment, making it a viable long-term investment.
The MACD histogram is positive and expanding (0.385), indicating bullish momentum. The RSI is at 87.553, signaling the stock is overbought, but this may reflect strong demand. Moving averages are converging, which could indicate a potential breakout. Key resistance levels are at R1: 8.179 and R2: 9.121, with the stock currently trading near these levels.
Analyst H.C. Wainwright raised the price target to $18 from $13, citing encouraging Phase 1 study results for paxalisib in treating triple-negative breast cancer.
Strong regular market performance with a 16.45% increase.
Bullish technical indicators, including a positive MACD and converging moving averages.
RSI indicates the stock is overbought, which could lead to short-term pullbacks.
Lack of recent news or significant trading trends from hedge funds or insiders.
Post-market decline of -2.10%, possibly indicating profit-taking.
No financial data available for assessment.
H.C. Wainwright maintains a Buy rating and raises the price target to $18 from $13, citing positive clinical trial results for paxalisib.
